BridgeBio Pharma (NASDAQ:BBIO | BBIO Price Prediction) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company’s transthyretin amyloid cardiomyopathy ...

BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...

BridgeBio PharmaBBIO said Sunday its heart-disease drug, Attruby, cut the risk of death almost in half in an exploratory study that one cardiologist says could be a game-changer for the disease.

U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial momentum Continued broad uptake among all patient types and HCP segments with ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BridgeBio Pharma recently announced that the FDA has accepted and granted Priority Review to its New Drug Application for oral BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9, with a PDUFA ...

BridgeBio Pharma (BBIO) stock slips as Raymond James downgrades the company on loss of exclusivity risks from Pfizer's ...

The company reiterated its goal of achieving "30-plus percent market share by volume in the years to come" for Attruby. Kumar stated, "The obvious growth in our portfolio today sits with the expansion ...

Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.

A BridgeBio Pharma drug developed for an increasingly prevalent cardiovascular condition has won FDA approval, marking a comeback for a company and a molecule with a turbulent history. But BridgeBio’s ...

On Friday, the FDA approved BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce ...

An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ATTR-CM.